Phase I Trial of Subcutaneous VDJ010 In Healthy Subjects and Patients With Ulcerative Colitis
A legfontosabb adatok
- Ki végzi
- Beijing VDJBio Co., LTD.
- Hol
- Kína6 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toboroz
- Fázis
- 1. fázis
- Résztvevők
- 48 fő, tervezett
- Kezdés
- 2024. aug. 9.
- Várható befejezés
- 2028. dec. 31.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
- A vizsgált kezelések
- Recombinant Human Interleukin-2 Fusion Protein with Human Serum Albumin (VDJ010)
- Placebo
- A regiszteradat frissítve
- 2026. november 12.
Ki vehet részt
- Életkor
- 18 év – 75 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Részt vehetnek
A regiszter összes feltétele (4)A regiszter feltételeinek elrejtése
Ki vehet részt
- Healthy Subjects:; Signed informed consent form and able to comply with the study protocol; Age ≥ 18 and ≤ 55 years (on the date of signing ICF); body weight ≥ 45.0 kg for women and ≥ 50.0 kg for men; BMI 18.0-28.0 kg/m² (inclusive); Normal function of major organs (heart, lung, liver, kidney); Negative serum pregnancy test for women of childbearing potential; willingness to use adequate contraceptive methods (e.g., abstinence, IUD, condoms) during the study and for 6 months after dosing
- UC Patients:; Age ≥ 18 and ≤ 75 years (on the date of signing ICF); male and female; Confirmed diagnosis of ulcerative colitis for ≥ 3 months prior to screening, per Chinese UC Diagnostic and Treatment Guidelines (2023, Xi'an), confirmed by endoscopy and histology within 14 days prior to randomization; Active UC defined as modified Mayo score ≥ 4 and ≤ 9, with stool frequency subscore ≥ 1, rectal bleeding subscore ≥ 1, and endoscopic subscore ≥ 2 (colonoscopy within 14 days acceptable); If UC history > 10 years, documented colonoscopy within 12 months prior to screening (or at screening). Those with family history of CRC, age > 50, or high-risk factors per investigator must have up-to-date CRC screening results; Negative serum pregnancy test for women of childbearing potential; male and female participants with reproductive potential must agree to use acceptable contraception during treatment and for 6 months after last dose; UC inflammation confirmed to extend proximal to the rectum, beyond the rectosigmoid junction (≥ 15 cm from anal verge) by colonoscopy; Voluntary participation with signed ICF; For patients on baseline UC therapies, the following washout/stability requirements must be met prior to randomization:; Oral 5-ASA agents: stable dose ≥ 2 weeks; Oral corticosteroids (prednisolone ≤ 25 mg/day or equivalent): stable dose ≥ 2 weeks Oral budesonide (≤ 9 mg/day): stable dose ≥ 2 weeks; Oral immunomodulators (MTX, AZA, 6-MP): stable dose ≥ 12 weeks
Ki nem vehet részt
- Healthy Subjects:; Allergic constitution (allergy to two or more drugs/foods); History of malignancy, neurological or psychiatric disorders (including epilepsy or dementia), heart failure, immunodeficiency, immunosuppressive disease, or IBD; or major surgery within 6 months prior to randomization; Severe bleeding tendency affecting venous access, or unable/unwilling to undergo venipuncture; Vaccination within 1 month prior to randomization; Prior treatment with anti-IL-2 or IL-2 receptor-targeted therapy; use of any biologic agent within 6 months prior to randomization or currently; Participation in another clinical trial with drug administration within 3 months prior to randomization; Blood donation (whole blood or components) or significant blood loss (≥ 400 mL) within 3 months prior to randomization; Active bacterial, viral, fungal, or parasitic infection, or any infection requiring systemic anti-infective therapy within 4 weeks prior to randomization; Use of any medication (e.g., warfarin, cyclosporine, theophylline, simvastatin, omeprazole, dextromethorphan, Chinese patent medicine) or health supplements (vitamins, dietary supplements) within 2 weeks, or prescription medication within 1 month prior to randomization; History of drug abuse within 1 year or positive urine drug screen; Alcoholism or regular alcohol consumption > 14 units/week within 3 months (1 unit = 360 mL beer or 45 mL 40% spirit or 150 mL wine); positive alcohol breath test; Average daily smoking > 5 cigarettes within 3 months prior to first dose, or unable to abstain from tobacco during the study; Excessive daily consumption of tea, coffee, or caffeinated beverages (> 8 cups/day, 1 cup = 250 mL); Clinically significant abnormal findings on comprehensive physical examination, including: abnormal vital signs; clinically significant abnormal lab tests (hematology, urinalysis, liver function, renal function, coagulation), with mandatory exclusions for ANC ≤ 1.5×10⁹/L, platelet count ≤ 100×10⁹/L, AST or ALT > 2×ULN; clinically significant ECG abnormalities, PR ≥ 210 ms, QRS ≥ 120 ms, QTcF ≥ 450 ms; Positive T-SPOT.TB (may accept up to 2-fold ULN if no TB history and no symptoms); Positive for HIV-Ab, TP-Ab, HCV-Ab, or HBsAg; Clinically significant abnormal findings for RF, anti-dsDNA, ANA, or anti-CCP; Planned surgery (including cosmetic, dental, or oral surgery) or planned vigorous physical activity (including contact or collision sports) during the study; Planned blood donation during the study; planned receipt of any biologic agent within 3 months after study drug administration; Any condition that, in the investigator's judgment, makes the subject unsuitable for or unable to complete the study; Female-specific exclusions:; Oral contraceptive use within 30 days or planned during study; Long-acting estrogen/progestin injection, contraceptive patch, vaginal ring, subcutaneous implant, or contraceptive injection within 6 months; Unprotected intercourse within 14 days prior to randomization; Pregnancy or lactation; Plans for pregnancy, sperm/egg donation during the study or within 3 months after study completion
- UC Patients; Crohn's disease (CD) or indeterminate colitis (IBD-U); Toxic megacolon, massive hemorrhage, perforation, sepsis, or intra-abdominal/peri-anal abscess requiring immediate surgical, endoscopic, or interventional treatment; History of ileostomy, proctocolectomy, or subtotal colectomy with ileorectal anastomosis; History of colorectal cancer, current CRC, serrated polyp with dysplasia, or atypical hyperplasia; Positive stool culture for pathogens or positive Clostridium difficile at screening. May be re-screened after adequate treatment and 30-day antibiotic washout; Clinically significant active infection; positive for HIV-Ab, TP-Ab, HCV-Ab, HBsAg (if HBsAg-negative but HBcAb-positive, add HBV-DNA; exclude if HBV-DNA > LLN), EBV-DNA, or CMV-DNA; Eosinophil count ≥ 2×ULN or diagnosed eosinophilia (including hereditary, primary, idiopathic, or secondary); Significant laboratory abnormalities:; Hb < 80 g/L; WBC < 2.5×10⁹/L; Platelets < 100×10⁹/L; Clinically significant ECG abnormalities: PR ≥ 210 ms, QRS ≥ 120 ms, QTcF < 350 ms or ≥ 450 ms (Fridericia correction); Creatinine ≥ 1.5×ULN; Total bilirubin > 34.2 μmol/L; ALT or AST > 2×ULN; GGT > 2×ULN; Abnormal thyroid function (hyper- or hypothyroidism); Positive T-SPOT.TB; Receipt of another investigational drug within 5 half-lives prior to planned first SC dose; History of malignancy within 5 years; Uncontrolled angina or symptomatic congestive heart failure (NYHA class III or IV); Allergy to any component of the study drug; Pregnancy or lactation; Prior treatment with IL-2 class drugs; use of biologics or small molecules (e.g., anti-TNF, anti-IL-12/23, IL-23 inhibitors, vedolizumab, JAK inhibitors, S1P receptor modulators) within 8 weeks or 5 half-lives (whichever longer) prior to baseline; cyclosporine or tacrolimus within 2 weeks; rectal formulations planned during study; Chinese herbal medicine for UC within 2 weeks prior to baseline; Unable to comply with study protocol or withdraws informed consent; Other conditions unsuitable for participation per investigator's judgment; Receipt of any live vaccine within 2 months prior to screening, BCG within 12 months, or planned live vaccination during the study
Alkalmassági kérdőív
Ez nem döntés: hogy ki vehet részt, azt csak a vizsgálat csapata mondhatja meg.
- Életkor
- Ulcerative colitis
Ez a vizsgálat jelenleg itt érhető el: Kína.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
This study adopted a multi-center, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose design, using recombinant human IL-2 fusion protein (VDJ010) administered subcutaneously to evaluate its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy Chinese subjects and patients with ulcerative colitis.
A vizsgálat 2 csoportja
- Recombinant human interleukin-2 fusion protein with human serum albumin (VDJ010) InjectionA vizsgált kezelés
Kezelés: Recombinant Human Interleukin-2 Fusion Protein with Human Serum Albumin (VDJ010)
- PlaceboPlacebo, összehasonlításként
Következő lépések
Az orvosodnak
Kérdőlap az orvosnak
PDF az orvosodnak: mit vizsgál a vizsgálat, ki vehet részt, és 2 kérdés a részvételi feltételekről, hellyel a válaszoknak és a jegyzeteknek.
PDF, US Letter, 1–2 oldal. A4 méretben
A vizsgálati csapatnak
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of VDJ010 for Subcutaneous Injection in Healthy Chinese Subjects and Patients With Ulcerative Colitis
- Kérdések a feltételekről
- Forrás: NCT07932691: ki vehet részt
- A regiszteradat frissítve
- 2026. november 12.